Natale Daniele Brunetti

Gender Differences in Takotsubo Syndrome.

Background: Male sex in takotsubo syndrome (TTS) has a low incidence and it is still not well characterized.

Objectives: The aim of the present study is to describe TTS sex differences.

Methods: TTS patients enrolled in the international multicenter GEIST (GErman Italian Spanish Takotsubo) registry were analyzed. Comparisons between sexes were performed within the overall cohort and using an adjusted analysis with 1:1 propensity score matching for age, comorbidities, and kind of trigger.

Results: In total, 286 (11%) of 2,492 TTS patients were men. Male patients were younger (age 69 ± 13 years vs 71 ± 11 years; p= 0.005), with higher prevalence of comorbid conditions (diabetes mellitus 25% vs 19%; p= 0.01; pulmonary diseases 21% vs 15%; p= 0.006; malignancies 25% vs 13%; p< 0.001) and physical trigger (55 vs 32% p< 0.01). Propensity-score matching yielded 207 patients from each group. After 1:1 propensity matching, male patients had higher rates of cardiogenic shock and in-hospital mortality (16% vs 6% and 8% vs 3%, respectively; both p< 0.05). Long-term mortality rate was 4.3% per patient-year (men 10%, women 3.8%). Survival analysis showed higher mortality rate in men during the acute phase in both cohorts (overall: p< 0.001; matched: p= 0.001); mortality rate after 60 days was higher in men in the overall (p= 0.002) but not in the matched cohort (p= 0.541). Within the overall population, male sex remained independently associated with both in-hospital (OR: 2.26; 95% CI: 1.16-4.40) and long-term mortality (HR: 1.83; 95% CI: 1.32-2.52). Conclusions: Male TTS is featured by a distinct high-risk phenotype requiring close in-hospital monitoring and long-term follow-up.

LEGGI TUTTO »

Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID-19: A Propensity Score-Matched Cohort Analysis of the HOPE-COVID-19 Registry.

Background: COVID-19 is an infectious illness, featured by an increased risk of thromboembolism. However, no standard antithrombotic therapy is currently recommended for patients hospitalized with COVID-19. The aim of this study was to evaluate safety and efficacy of additional therapy with ASA over prophylactic anticoagulation (PAC) in patients hospitalized with COVID-19 and its impact on survival.

Methods and Results: a total of 8.168 patients hospitalized for COVID-19 were enrolled in a multicenter-international prospective registry (HOPE COVID-19). Clinical data and inhospital complications, including mortality, were recorded. Study population included patients treated with PAC or with PAC and ASA. A comparison of clinical outcomes between patients treated with PAC versus PAC and ASA was performed using an adjusted analysis with propensity score matching. Of 7.824 patients with complete data, 360 (4.6%) received PAC and ASA a nd 2 .949 ( 37.6%) P AC. P ropensity-score matching yielded 298 patients from each group. In the propensity score-matched population, cumulative incidence of in-hospital mortality was lower in patients treated with PAC and ASA versus PAC (15% versus 21%, Log Rank P=0.01). At multivariable analysis in propensity matched population of patients with COVID-19, including age, sex, hypertension, diabetes, kidney failure, and invasive ventilation, ASA treatment was associated with lower risk of in-hospital mortality (hazard ratio [HR], 0.62; [95% CI 0.42-0.92], P=0.018).

Conclusions: combination PAC and ASA was associated with lower mortality risk among patients hospitalized with COVID-19 in a propensity score matched population compared to PAC alone.

LEGGI TUTTO »
Cerca un articolo
Gli articoli più letti
Rubriche
Leggi i tuoi articoli salvati
La tua lista è vuota